New drug CD-001 for advanced head and neck cancers
Part of Cancer clinical trials.
This trial tests a new drug called CD-001 for advanced head and neck cancer. The drug is given to see if it is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have advanced head and neck cancer that hasn't responded to standard treatments, or you couldn't tolerate them.
- You are able to care for yourself (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
This trial tests a new drug that may help people with advanced solid tumors that have not responded to other treatments. The drug is given as an injection and aims to stop cancer growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests a new combination treatment for head and neck cancer that has come back or spread and has a specific genetic change (CDKN2A mutation). The treatment combines an antibody-drug conjugate (a targeted therapy) with a CDK4/6 inhibitor (a drug that helps stop cancer cells from dividing). It may help people who have already tried standard treatments like immunotherapy or chemotherapy.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
This trial tests a new targeted drug (SYS6010) compared with standard single-drug treatments for advanced head and neck cancer that has not responded to previous therapies. The goal is to see if this new drug can shrink tumors or slow cancer growth better than the usual options.
Hear when a new Head &Amp; Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.